COVID-19 one year later: a retrospect of CRISPR-Cas system in combating COVID-19

Release time:2023-02-01

Impact Factor:10.75

DOI number:10.7150/ijbs.60655

Affiliation of Author(s):Xiangya Hospital, Central South University

Teaching and Research Group:Department of Clinical Pharmacology

Journal:Int J Biol Sci

Place of Publication:Australia

Funded by:National Natural Science Foundation of China

Key Words:COVID-19; CRISPR-Cas; SARS-CoV-2; diagnosis; gene editing; mechanism research;

Abstract:Coronavirus disease 2019 (COVID-19), an infectious disease caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has posed a persistent global threat. The transmission of SARS-CoV-2 is wide and swift. Rapid detection of the viral RNA and effective therapy are imperative to prevent the worldwide spread of the new infectious disease. Clustered Regularly-Interspaced Short Palindromic Repeats (CRISPR)- CRISPR-associated protein (Cas) system is an RNA-directed adaptive immune system, and it has been transformed into a gene editing tool. Applications of CRISPR-Cas system involves in many fields, such as human gene therapy, drug discovery and disease diagnosis. Under the background of COVID-19 pandemic, CRISPR-Cas system shows hidden capacity to fight the emergency in many aspects. This review will focus on the role of gene editing in COVID-19 diagnosis and treatment. We will describe the potential use of CRISPR-Cas-based system in combating COVID-19, from diagnosis to treatment. Furthermore, the limitation and perspectives of this novel technology are also evaluated.

First Author:Yan Zhan

Indexed by:Review

Correspondence Author:Ji-Ye Yin, Xiang-Ping Li

Discipline:Medicine

First-Level Discipline:Pharmaceutical Science

Document Type:J

Volume:17

Issue:8

Page Number:2080-2088

Number of Words:6220

ISSN No.:1449-2288

Translation or Not:no

Date of Publication:2021-05-13

Included Journals:SCI

Links to published journals:https://www.ijbs.com/v17p2080.htm